Conditions:   Hemophilia A;   Hemophilia B;   Vitamin D Deficiency
Intervention:   Dietary Supplement: Vitamin D and calcium
Sponsors:   Virginia Commonwealth University;   CSL Behring
Recruiting - verified March 2010

Condition:   Multiple Myeloma
Intervention:   Drug: AZD6244 hydrogen sulfate capsules
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Multiple Myeloma
Intervention:  
Sponsor:   Celgene Corporation
Recruiting - verified March 2010

Conditions:   Myeloma;   Stem Cell Transplantation
Interventions:   Drug: Lenalidomide;   Drug: Melphalan
Sponsor:   M.D. Anderson Cancer Center
Recruiting - verified March 2010

Condition:   Waldenstrom's Macroglobulinemia
Interventions:   Drug: pomalidomide;   Drug: dexamethasone;   Drug: rituximab
Sponsors:   Dana-Farber Cancer Institute;   Celgene Corporation
Not yet recruiting - verified March 2010

Conditions:   Cancer Survivor;   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Testicular Germ Cell Tumor
Interventions:   Genetic: DNA analysis;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: laboratory biomarker analysis
Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With T(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With T(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With T(8;21)(q22;q22);   Atypical Chronic Myeloid Leukemia;   Blastic Phase Chronic Myelogenous Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   De Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Myelodysplastic/Myeloproliferative Disease, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma
Interventions:   Drug: plerixafor;   Biological: filgrastim;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation
Sponsor:   Fred Hutchinson Cancer Research Center
Not yet recruiting - verified February 2010

Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Peripheral T-Cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Splenic Marginal Zone Lymphoma;   Waldenstrom Macroglobulinemia
Interventions:   Drug: everolimus;   Drug: lenalidomide;   Other: laboratory biomarker analysis;   Genetic: polymorphism analysis;   Other: immunohistochemistry staining method;   Genetic: microarray analysis;   Genetic: fluorescence in situ hybridization
Sponsor:   Mayo Clinic
Not yet recruiting - verified February 2010

Conditions:   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions:   Drug: plerixafor;   Biological: filgrastim;   Drug: cyclophosphamide;   Procedure: autologous hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
Sponsor:   City of Hope Medical Center
Not yet recruiting - verified February 2010

Condition:   Purpura, Thrombocytopenic, Idiopathic
Interventions:   Drug: Eltrombopag;   Drug: Eltrombopag
Sponsor:   GlaxoSmithKline
Recruiting - verified February 2010

Condition:   Multiple Myeloma
Intervention:   Drug: KW-2478 and bortezomib
Sponsors:   Kyowa Hakko Kirin Pharma, Inc.;   Kyowa Hakko Kirin UK, Ltd.;   Kyowa Hakko Kirin Company, Limited
Not yet recruiting - verified January 2010

Condition:   Severe Hemophilia A
Interventions:   Drug: FVIII Concentrates;   Drug: FVIII/VWF concentrates
Sponsors:   City of Hope Medical Center;   Grifols Biologicals Inc.;   CSL Behring;   Talecris Biotherapeutics;   Biotest Pharmaceuticals Corporation
Recruiting - verified March 2010

Condition:   Multiple Myeloma
Interventions:   Drug: lenalidomide;   Drug: melphalan
Sponsors:   Weill Medical College of Cornell University;   Celgene Corporation
Recruiting - verified March 2010

Condition:   Refractory Multiple Myeloma
Interventions:   Drug: bendamustine hydrochloride;   Drug: lenalidomide;   Drug: dexamethasone
Sponsor:   Mayo Clinic
Recruiting - verified March 2010

Conditions:   Graft Versus Host Disease;   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   De Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Waldenstrom Macroglobulinemia
Interventions:   Drug: rituximab;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Drug: anti-thymocyte globulin;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis;   Biological: graft versus host disease prophylaxis/therapy;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: busulfan;   Radiation: total-body irradiation;   Biological: graft-versus-tumor induction therapy;   Biological: immunosuppressive therapy
Sponsor:   University of Nebraska
Recruiting - verified March 2010

Conditions:   Blood Coagulation Disorders;   Hemophilia A
Interventions:   Biological: Recombinant Factor VIII (Kogenate PF, BAY81-8973);   Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222);   Biological: Recombinant Factor VIII (Kogenate PF, BAY81-8973);   Biological: Recombinant Factor VIII (Kogenate PF, BAY81-8973)
Sponsor:   Bayer
Recruiting - verified March 2010

Condition:   Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Intervention:   Biological: Romiplostim
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Multiple Myeloma
Interventions:   Drug: carfilzomib, lenalidomide plus dexamethasone;   Drug: carfilzomib, lenalidomide plus dexamethasone
Sponsors:   University of Michigan Cancer Center;   Onyx Therapeutics, Inc.;   Celgene Corporation
Recruiting - verified February 2010

Condition:   Multiple Myeloma
Intervention:   Drug: CEP-18770
Sponsor:   Cephalon
Recruiting - verified March 2010

Condition:   Multiple Myeloma
Interventions:   Drug: Perifosine;   Drug: Perifosine Placebo;   Drug: Bortezomib;   Drug: Dexamethasone
Sponsors:   Keryx / AOI Pharmaceuticals, Inc.;   Dana-Farber Cancer Institute
Recruiting - verified March 2010

Conditions:   Multiple Myeloma;   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions:   Drug: plerixafor;   Drug: filgrastim
Sponsor:   Mayo Clinic
Recruiting - verified March 2010

Condition:   Immune Thrombocytopenic Purpura
Interventions:   Drug: Dexamethasone USP Micronized;   Drug: Prednisone
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Methemoglobinemia;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm
Interventions:   Drug: chemotherapy;   Drug: dapsone;   Other: medical chart review;   Procedure: assessment of therapy complications
Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified December 2009

Conditions:   Pancreatic Cancer;   Ductal Adrenocarcinoma;   Exocrine Pancreatic Cancer
Intervention:   Drug: PCI-27483
Sponsor:   Pharmacyclics
Recruiting - verified February 2010

Condition:   Multiple Myeloma
Intervention:   Drug: IMGN901
Sponsor:   ImmunoGen, Inc.
Recruiting - verified March 2010

Condition:   Haemophilia A
Interventions:   Drug: recombinant factor VIII (N8);   Drug: recombinant factor VIII (N8)
Sponsor:   Novo Nordisk
Recruiting - verified March 2010

Condition:   Hemophilia B
Intervention:   Genetic: Gene Transfer
Sponsors:   St. Jude Children's Research Hospital;   Stanford University;   Katharine Dormandy Haemophilia Centre and Haemostasis Unit
Recruiting - verified March 2010

Condition:   Congenital FXIII Deficiency
Intervention:   Drug: recombinant factor XIII
Sponsor:   Novo Nordisk
Recruiting - verified March 2010

Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplasia;   Non-Hodgkin's Lymphoma;   Hodgkin's Disease;   Multiple Myeloma;   Myelofibrosis;   Anemia, Aplastic;   Hemoglobinuria, Paroxysmal
Intervention:   Drug: Basiliximab
Sponsor:   Indiana University School of Medicine
Recruiting - verified March 2010

Conditions:   Leukemia;   Non-Hodgkins Lymphoma;   Hodgkins Lymphoma;   MDS;   Multiple Myeloma
Interventions:   Drug: EPOCH-F/R;   Drug: FLAG;   Drug: Transplant Preparative Regimen (Flu/Cy/Mes);   Drug: GVHD Prophylaxis (tacrolimus and sirolimus);   Procedure: Double Cord Blood Transplantation
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified November 2009

Condition:   Multiple Myeloma
Interventions:   Procedure: Apheresis;   Procedure: Stem Cell Transplantation;   Drug: Melphalan
Sponsor:   M.D. Anderson Cancer Center
Not yet recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm
Interventions:   Biological: trivalent influenza vaccine;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis
Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
Recruiting - verified August 2009

Conditions:   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: everolimus;   Drug: panobinostat;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
Recruiting - verified August 2009

Condition:   Haemophilia A or B With Inhibitors
Interventions:   Drug: activated recombinant human factor VII, long acting;   Drug: activated recombinant human factor VII, long acting;   Drug: activated recombinant human factor VII, long acting
Sponsor:   Novo Nordisk
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm;   Viral Infection
Interventions:   Other: cytology specimen collection procedure;   Other: fluorescent antibody technique;   Procedure: assessment of therapy complications
Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
Recruiting - verified August 2009

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Psychosocial Effects of Cancer and Its Treatment;   Therapy-related Toxicity
Interventions:   Behavioral: exercise intervention;   Behavioral: telephone-based intervention;   Dietary Supplement: dietary intervention;   Other: educational intervention;   Other: questionnaire administration;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: assessment of therapy complications;   Procedure: peripheral blood stem cell transplantation;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment;   Procedure: standard follow-up care
Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Condition:   Factor XIII Deficiency
Intervention:   Biological: FXIII Concentrate Human
Sponsor:   CSL Behring
Recruiting - verified March 2010

Conditions:   Multiple Myeloma and Plasma Cell Neoplasm;   Precancerous Condition
Interventions:   Dietary Supplement: defined green tea catechin extract;   Genetic: gene expression analysis;   Genetic: protein analysis;   Other: laboratory biomarker analysis
Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Condition:   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Biological: anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells;   Genetic: gene expression analysis;   Genetic: protein expression analysis;   Other: enzyme-linked immunosorbent assay;   Other: flow cytometry;   Other: immunohistochemistry staining method;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:   Other: 3'-deoxy-3'-[18F]fluorothymidine
Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified September 2009

Conditions:   Primary Myelofibrosis;   Post-Polycythemia Vera;   Post-Essential Thrombocytopenia
Interventions:   Drug: Panobinostat;   Drug: Panobinostat
Sponsor:   Novartis
Recruiting - verified March 2010

Condition:   Multiple Myeloma
Interventions:   Drug: Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection;   Drug: Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free)
Sponsor:   CyDex Pharmaceuticals, Inc.
Recruiting - verified February 2010

Condition:   Factor X Deficiency
Intervention:   Biological: Human Coagulation FACTOR X
Sponsor:   Bio Products Laboratory
Recruiting - verified March 2010

Conditions:   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Precancerous Condition
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Multiple Myeloma
Intervention:   Drug: bendamustine as combination therapy with bortezomib
Sponsor:   Cephalon
Recruiting - verified March 2010

Condition:   Multiple Myeloma
Interventions:   Drug: Bendamustine;   Drug: Melphalan;   Drug: Bendamustine;   Drug: Bendamustine;   Drug: Bendamustine;   Drug: Bendamustine
Sponsor:   Weill Medical College of Cornell University
Recruiting - verified March 2010

Conditions:   Hematopoietic/Lymphoid Cancer;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Primary Central Nervous System Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Multiple Myeloma;   Splenic Marginal Zone Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   Waldenstrom Macroglobulinemia
Interventions:   Drug: panobinostat;   Drug: everolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Other: flow cytometry;   Other: immunohistochemistry staining method;   Other: western blotting
Sponsor:   Mayo Clinic
Recruiting - verified March 2010

Condition:   Multiple Myeloma
Interventions:   Drug: 328 plus VMP (Part 1, Part 2-Arm A);   Drug: VMP Alone (Part 2-Arm B)
Sponsor:   Centocor, Inc.
Recruiting - verified February 2010

Condition:   Immune Thrombocytopenic Purpura
Interventions:   Drug: eltrombopag;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Conditions:   Thrombocytopenia;   Idiopathic Thrombocytopenic Purpura
Intervention:   Biological: romiplostim
Sponsor:   Amgen
Recruiting - verified March 2010

Conditions:   Multiple Myeloma and Plasma Cell Neoplasm;   Precancerous Condition
Interventions:   Genetic: cytogenetic analysis;   Genetic: microarray analysis;   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions:   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: polymorphism analysis;   Genetic: proteomic profiling;   Other: flow cytometry;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: biopsy
Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified October 2008

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: fentanyl citrate;   Other: pharmacological study
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Cancer Institute of New Jersey;   National Cancer Institute (NCI)
Recruiting - verified August 2008

Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nausea and Vomiting;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions:   Other: immunoenzyme technique;   Other: laboratory biomarker analysis;   Other: medical chart review
Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Conditions:   Breast Cancer;   Hypercalcemia of Malignancy;   Colon Cancer;   Endocrine Cancer;   Head and Neck Cancer;   Kidney Cancer;   Lung Cancer;   Lymphoma;   Metastatic Cancer;   Multiple Myeloma;   Parathyroid Neoplasms;   Renal Cancer;   Thyroid Cancer;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Non-small Cell Lung Cancer
Intervention:   Drug: denosumab
Sponsor:   Amgen
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Kidney Cancer;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonneoplastic Condition;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: sunitinib malate;   Other: liquid chromatography;   Other: mass spectrometry;   Other: pharmacological study
Sponsors:   AIDS Associated Malignancies Clinical Trials Consortium;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Factor XIII Deficiency
Intervention:   Biological: FXIII Concentrate Human
Sponsor:   CSL Behring
Recruiting - verified March 2010

Condition:   Advanced Cancer, Various, NOS
Interventions:   Drug: BMS-833923;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Bortezomib
Sponsors:   Bristol-Myers Squibb;   Exelixis
Recruiting - verified December 2009

Conditions:   Breast Cancer;   Lung Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:   Procedure: assessment of therapy complications
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Solid Tumors;   Lymphoma, Non-Hodgkin;   Multiple Myeloma;   Leukemia, Lymphocytic, Chronic. B-Cell
Intervention:   Drug: SCH 727965
Sponsor:   Schering-Plough
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Musculoskeletal Complications;   Pain;   Prostate Cancer;   Urinary Complications
Intervention:   Drug: zoledronic acid
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Fanconi Anemia;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm;   Paroxysmal Nocturnal Hemoglobinuria
Interventions:   Biological: anti-thymocyte globulin;   Biological: graft-versus-tumor induction therapy;   Drug: fludarabine phosphate;   Drug: melphalan;   Procedure: allogeneic hematopoietic stem cell transplantation;   Radiation: total-body irradiation
Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified November 2009

Condition:   Haemophilia A
Interventions:   Drug: recombinant factor VIII (N8);   Procedure: Blood drawn for laboratory testing
Sponsor:   Novo Nordisk
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions:   Other: educational intervention;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Other: survey administration;   Procedure: psychosocial assessment and care;   Procedure: stress management therapy;   Procedure: support group therapy
Sponsors:   University of Colorado, Denver;   National Cancer Institute (NCI)
Recruiting - verified January 2009

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Infection;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Therapy-related Toxicity
Interventions:   Biological: immunosuppressive therapy;   Other: immunological diagnostic method;   Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Condition:   Waldenstrom's Macroglobulinemia
Intervention:   Biological: Ofatumumab
Sponsor:   GlaxoSmithKline
Recruiting - verified February 2010

Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Chronic Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Multiple Myeloma;   Waldenstrom's Macroglobulinemia;   Myelodysplastic Syndrome;   Philadelphia Chromosome-negative CML;   Myeloid Metaplasia;   Myelofibrosis;   Advanced Polycythemia;   Non-Hodgkins Lymphoma
Intervention:   Drug: TAK-901
Sponsor:   Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Drug: fludarabine phosphate;   Drug: melphalan;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Radiation: intensity-modulated radiation therapy;   Radiation: tomotherapy;   Radiation: total marrow irradiation;   Radiation: total nodal irradiation
Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: natural killer cell therapy;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Radiation: total-body irradiation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified August 2009

Conditions:   Hematologic Disease;   Blood Coagulation Disorders
Interventions:   Behavioral: Recombinant Factor VIII (Kogenate, BAY 14-2222);   Behavioral: Recombinant Factor VIII (Kogenate, BAY 14-2222);   Behavioral: Recombinant Factor VIII (Kogenate, BAY 14-2222)
Sponsor:   Bayer
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: tacrolimus;   Genetic: polymerase chain reaction;   Other: pharmacological study;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
Sponsor:   Blood and Marrow Transplant Group of Georgia
Recruiting - verified June 2009

Conditions:   Wiskott-Aldrich Syndrome (WAS);   X-linked Thrombocytopenia
Intervention:   Drug: Interleukin-2
Sponsors:   Children's Hospital of Philadelphia;   Novartis
Recruiting - verified March 2010

Condition:   Multiple Myeloma
Intervention:   Drug: BIW-8962
Sponsor:   Kyowa Hakko Kirin Pharma, Inc.
Recruiting - verified January 2009

Conditions:   Chronic Myeloproliferative Disorders;   Depression;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Psychosocial Effects of Cancer and Its Treatment;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Other: medical chart review;   Other: questionnaire administration;   Procedure: psychosocial assessment and care
Sponsors:   Cancer Institute of New Jersey;   National Cancer Institute (NCI)
Recruiting - verified August 2008

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Lymphoma;   Multiple Myeloma;   Leukemia, Myelomonocytic, Chronic
Intervention:   Drug: azacitidine
Sponsor:   Celgene Corporation
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Drug: cyclosporine ophthalmic emulsion;   Other: placebo
Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:   Other: educational intervention
Sponsors:   Fox Chase Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Conditions:   Myelofibrosis;   Myeloproliferative Disorders;   Polycythemia Vera;   Essential Thrombocythemia
Intervention:   Drug: SB1518
Sponsor:   S*BIO
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Long-term Effects Secondary to Cancer Therapy in Children;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Other: survey administration;   Procedure: assessment of therapy complications;   Procedure: long-term screening;   Procedure: study of high risk factors
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Pain;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: methadone hydrochloride;   Drug: morphine sulfate;   Drug: oxycodone hydrochloride
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Conditions:   Neoplasms;   Lymphoma;   Multiple Myeloma
Interventions:   Drug: SCH 900105;   Drug: SCH 900105;   Drug: SCH 900105;   Drug: Erlotinib
Sponsors:   Schering-Plough;   AVEO Pharmaceuticals, Inc.
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Conditions:   Chronic Myeloproliferative Disorders;   Fatigue;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Dietary Supplement: American ginseng;   Other: placebo
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: rituximab;   Drug: busulfan;   Drug: carmustine;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: melphalan;   Radiation: total-body irradiation
Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified January 2010

Conditions:   Adrenocortical Carcinoma;   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition;   Sarcoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Biological: cixutumumab;   Drug: temsirolimus
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Pain;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Other: questionnaire administration;   Procedure: acupressure therapy;   Procedure: biopsy;   Procedure: bone marrow aspiration;   Procedure: pain therapy
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Conditions:   Myelofibrosis;   Essential Thrombocythemia;   Polycythemia Vera
Intervention:   Drug: CEP-701 (Lestaurtinib)
Sponsor:   Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010

Conditions:   Myelofibrosis;   Idiopathic Myelofibrosis;   Essential Thrombocythemia;   Polycythemia Vera
Intervention:  
Sponsor:   Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010

Conditions:   Polycythemia Vera;   Essential Thrombocythemia;   Idiopathic Myelofibrosis
Intervention:  
Sponsor:   Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010

Conditions:   Myeloproliferative Disease;   Myelofibrosis;   Idiopathic Myelofibrosis;   Essential Thrombocythemia;   Polycythemia Vera
Intervention:  
Sponsor:   Myeloproliferative Disorders-Research Consortium
Recruiting - verified February 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Pain;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Other: educational intervention;   Other: medical chart review;   Other: questionnaire administration;   Procedure: pain therapy;   Procedure: quality-of-life assessment
Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified October 2009

Conditions:   Multiple Myeloma;   Primary Amyloidosis
Interventions:   Drug: Melphalan;   Procedure: Stem Cell Infusion;   Behavioral: Questionnaires;   Drug: Granulocyte-colony stimulating factor (G-CSF);   Procedure: Apheresis
Sponsor:   M.D. Anderson Cancer Center
Recruiting - verified March 2010

Condition:   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: bortezomib;   Drug: dexamethasone;   Drug: lenalidomide
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition
Interventions:   Biological: alemtuzumab;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation
Sponsor:   Baylor College of Medicine
Recruiting - verified June 2009

Condition:   Hemophilia A
Interventions:   Drug: Recombinant Anti-hemophilic Factor VIII (Kogenate®FS);   Drug: Recombinant Anti-hemophilic Factor VIII (Kogenate®FS)
Sponsor:   Bayer
Recruiting - verified March 2010

Conditions:   Multiple Myeloma;   Plasma Cell Leukemia;   Lymphoma;   Chronic Lymphocytic Leukemia
Interventions:   Drug: Fludarabine/Busulfan x 4 days;   Procedure: stem cell transplant
Sponsors:   University of Michigan Cancer Center;   PDL BioPharma, Inc.
Recruiting - verified March 2010

Condition:   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: lenalidomide;   Drug: melphalan;   Drug: prednisone;   Drug: thalidomide
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Infection;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition;   Secondary Myelofibrosis;   Small Intestine Cancer
Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methotrexate;   Drug: sirolimus;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: hematopoietic stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Condition:   Multiple Myeloma
Interventions:   Drug: Dasatinib;   Drug: Bortezomib;   Drug: Dexamethasone
Sponsor:   Bristol-Myers Squibb
Recruiting - verified January 2010

Condition:   Multiple Myeloma
Intervention:   Drug: Dasatinib + Lenalidomide + Dexamethasone
Sponsor:   Bristol-Myers Squibb
Recruiting - verified January 2010

Condition:   Von Willebrand Disease
Intervention:   Biological: Alphanate SD/HT
Sponsor:   Grifols Biologicals Inc.
Recruiting - verified March 2010

Condition:   Watermelon Stomach
Interventions:   Procedure: cryotherapy;   Procedure: Argon Plasma Coagulation
Sponsor:   Mayo Clinic
Recruiting - verified March 2010

Condition:   Multiple Myeloma
Interventions:   Drug: Bortezomib;   Drug: Dexamethasone;   Drug: PD 0332991
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Childhood Germ Cell Tumor;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Neuroblastoma;   Testicular Germ Cell Tumor;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: busulfan;   Drug: carboplatin;   Drug: carmustine;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: melphalan;   Drug: thiotepa;   Radiation: total-body irradiation
Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Condition:   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: bortezomib;   Drug: dexamethasone;   Drug: lenalidomide
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Biological: alemtuzumab;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: prednisone;   Drug: sirolimus;   Drug: tacrolimus;   Drug: vincristine sulfate
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified July 2009

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: etoposide;   Drug: methotrexate;   Drug: rasburicase;   Drug: sirolimus;   Drug: tacrolimus;   Other: flow cytometry;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
Sponsor:   Massachusetts General Hospital
Recruiting - verified April 2008

Condition:   Chronic Idiopathic Thrombocytopenic Purpura
Interventions:   Biological: Gammaplex, intravenous immunoglobulin;   Biological: Gammaplex;   Biological: Gammaplex
Sponsor:   Bio Products Laboratory
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Drug: beclomethasone dipropionate;   Drug: methotrexate;   Drug: tacrolimus;   Other: placebo
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Condition:   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Biological: filgrastim;   Drug: dexamethasone;   Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Condition:   Childhood Obesity
Interventions:   Other: Diet;   Other: Diet
Sponsors:   Children's Hospital Boston;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2010

Condition:   Myeloma
Intervention:   Other: Telephone Questionnaire
Sponsors:   M.D. Anderson Cancer Center;   AnorMED
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Biological: graft-versus-tumor induction therapy;   Biological: therapeutic allogeneic lymphocytes;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methotrexate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
Sponsors:   Wake Forest University;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Biological: alemtuzumab;   Biological: therapeutic allogeneic lymphocytes;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
Sponsors:   UNC Lineberger Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified July 2008

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Biological: anti-thymocyte globulin;   Biological: sargramostim;   Biological: therapeutic allogeneic lymphocytes;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: tacrolimus;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
Sponsors:   UNC Lineberger Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified July 2008

Condition:   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Biological: aflibercept;   Other: flow cytometry;   Other: immunoenzyme technique;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   Weill Medical College of Cornell University;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Multiple Myeloma;   Leukemia;   Lymphoma
Interventions:   Drug: Fludarabine;   Drug: Melphalan;   Procedure: Umbilical Cord Blood;   Drug: Rituximab;   Other: Peripheral Blood Stem Cell Infusion
Sponsor:   M.D. Anderson Cancer Center
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Precancerous Condition;   Secondary Myelofibrosis;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: pemetrexed disodium;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsor:   Robert H. Lurie Cancer Center
Recruiting - verified July 2009

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Secondary Myelofibrosis;   Small Intestine Cancer
Interventions:   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2009

Condition:   Idiopathic Thrombocytopenic Purpura
Intervention:   Drug: eltrombopag olamine (SB-497115-GR)
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Multiple Myeloma
Intervention:   Drug: BB-10901
Sponsor:   ImmunoGen, Inc.
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified December 2009

Condition:   Severe Hemophilia A
Intervention:   Drug: Alphanate SD/HT
Sponsor:   Grifols Biologicals Inc.
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Infection;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
Intervention:   Drug: moxifloxacin hydrochloride
Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Condition:   Antithrombin III Deficiency
Intervention:   Drug: Plasma-derived AT-III concentrate
Sponsor:   Grifols Biologicals Inc.
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsors:   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)
Recruiting - verified October 2008

Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: CD4+CD25+ regulatory T cells;   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
Sponsors:   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)
Recruiting - verified September 2009

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Unusual Cancers of Childhood
Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Biological: therapeutic allogeneic lymphocytes;   Drug: busulfan;   Drug: carmustine;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: cytarabine;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: radiation therapy
Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified June 2007

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: graft-versus-tumor induction therapy;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: radiation therapy
Sponsor:   James P. Wilmot Cancer Center
Recruiting - verified June 2007

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition
Interventions:   Biological: therapeutic allogeneic lymphocytes;   Drug: busulfan;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified January 2009

Condition:   Multiple Myeloma
Interventions:   Procedure: Stem Cell Transplant;   Drug: cyclophosphamide, melphalan;   Drug: Thalidomide and Dexamethasone
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2010

Conditions:   Leukemia, Myeloid, Chronic;   AML;   Leukemia, Lymphocytic, Acute;   MDS;   Leukemia, Lymphocytic, Chronic;   JMML;   Hodgkin's Disease;   Non-Hodgkin's Lymphoma;   Multiple Myeloma
Interventions:   Procedure: Stem Cell Transplant;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Busulfan
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2010

Condition:   Burns
Intervention:   Drug: Recombinant Factor VIIa
Sponsor:   United States Army Institute of Surgical Research
Recruiting - verified February 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Radiation: radiation therapy
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: bone marrow ablation with stem cell support
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: alemtuzumab;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
Intervention:   Drug: fenretinide
Sponsors:   California Cancer Consortium;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Sarcoma;   Testicular Germ Cell Tumor
Interventions:   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Drug: pentostatin
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: graft-versus-tumor induction therapy;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified December 2009

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: filgrastim;   Biological: graft-versus-tumor induction therapy;   Biological: rituximab;   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: prednisone;   Drug: vincristine sulfate;   Procedure: peripheral blood stem cell transplantation
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified July 2009

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: therapeutic allogeneic lymphocytes;   Drug: sirolimus
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified November 2007

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Sarcoma;   Testicular Germ Cell Tumor
Intervention:   Biological: therapeutic allogeneic lymphocytes
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified December 2009

Condition:   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: melphalan;   Drug: thalidomide;   Procedure: peripheral blood stem cell transplantation
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Procedure: umbilical cord blood transplantation;   Drug: methylprednisolone
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: anti-thymocyte globulin;   Biological: graft-versus-tumor induction therapy;   Biological: sargramostim;   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation
Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Conditions:   Brain and Central Nervous System Tumors;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Genetic: genetic linkage analysis;   Genetic: microarray analysis;   Other: counseling intervention;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: evaluation of cancer risk factors
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified April 2007

Conditions:   Leukemia;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Genetic: chromosomal translocation analysis;   Genetic: cytogenetic analysis
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Oral Complications;   Ovarian Cancer;   Pain;   Sarcoma
Interventions:   Procedure: management of therapy complications;   Procedure: pain therapy
Sponsor:   Medical College of Wisconsin
Recruiting - verified June 2009

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: anti-thymocyte globulin;   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Procedure: peripheral blood stem cell transplantation
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2009